SUNNYVALE, CA, April 16 /CNW/ - Molecular Devices, a division of MDS
Analytical Technologies and a leader in innovative solutions for drug
discovery and life sciences, today announced a new aequorin option for its
FLIPR Tetra(R) fluorometric imaging plate reader. This addition to the FLIPR
Tetra system includes the uniquely designed camera that can detect both
fluorescence and aequorin luminescence - and a new cell suspension option.
Both the camera and cell suspension option were optimized on FLIPR Tetra to
enable researchers to expand their calcium mobilization assays to include
aequorin luminescence measurements. FLIPR Tetra with aequorin option will
debut at the Society for Biomolecular Sciences Conference & Exhibition,
April 15-19, 2007 at the Palais des Congrès de Montréal, Montréal, Canada in
Molecular Devices' booth No.401.
Unique to the FLIPR Tetra system is a single camera to monitor aequorin
luminescence and fluorescence-based calcium and membrane potential assays.
Sensitivity can be adjusted to the appropriate assay signal window to detect
dim aequorin cell lines while maintaining the ability to screen using
traditional fluorescence methods.
The new aequorin option enables cell suspension assays, thereby
minimizing cell preparation time and reducing assay costs. The cell suspension
feature also increases throughput by simultaneously delivering cells in up to
1536 wells using proven FLIPR(R) pipettor technology. FLIPR Tetra optics
(LEDs, emission filters, and standard camera) and automation capabilities are
available for site-specific laboratory configuration.
"With the addition of the aequorin option for FLIPR Tetra, we can offer
FLIPR(R) users the added benefits of reduced assay costs and fewer technical
requirements associated with running aequorin applications," said Andy Boorn,
President of MDS Analytical Technologies. "We are excited to provide the
industry with another innovative screening solution that will enable higher
throughput and lower-cost options for drug discovery."
The FLIPR Tetra system was introduced in June 2004, and was the first
system to enable researchers to significantly increase throughput of
cell-based assays by measuring 1536 kinetic measurements simultaneously, thus
significantly reducing screening time and reagent consumption. This system
also offers traditional 96- and 384-well fluidics, easily convertible by the
user within minutes, providing a seamless transition between higher-volume
assays to those that require sub-microliter volume additions.
About MDS Inc.
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs and diagnosis and treatment of disease. We are a leading
global provider of pharmaceutical contract research, medical isotopes for
molecular imaging, radiotherapeutics, and analytical instruments. MDS has more
than 6,200 highly skilled people in 28 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
About MDS Analytical Technologies
MDS Analytical Technologies is a newly established MDS Inc. business unit
and is a world-class organization comprised of two main lines of business. The
Sciex product portfolio offers proven market leadership in mass spectrometry
through its joint ventures with two of the world's leading analytical
instrumentation and life sciences companies, Applied Biosystems, a business of
the Applera Corporation and PerkinElmer Inc. The Molecular Devices product
portfolio is the gold standard in high-performance bioanalytical measurement
systems that accelerate and improve drug discovery and other life sciences
research. Find out more at www.moleculardevices.com or www.mdssciex.com
For further information:
For further information: Media: Jennifer McKie, Director of Marketing
for FLIPR Products, (408) 747-3514, Jennifer.McKie@moldev.com; Investors:
Sharon Mathers, Senior Vice-President, Investor Relations and External
Communications, MDS Inc., (416) 675-6777 x 34721, email@example.com